APELLIS PHARMACEUTICALS INC. - COMMON STOCK

Apellis Pharmaceuticals to Host Conference Call on February 28, 2022 to Discuss Fourth Quarter and Full Year 2021 Financial Results

22 Feb 2022 07:00:01 By Nasdaq GlobeNewswire

Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

06 Jan 2022 16:05:00 By Nasdaq GlobeNewswire

Apellis Pharmaceuticals to Present at the 40th Annual J.P. Morgan Healthcare Conference

03 Jan 2022 07:00:00 By Nasdaq GlobeNewswire

Apellis and Sobi Announce EU Approval of Aspaveli® (pegcetacoplan) for Treatment of PNH

15 Dec 2021 07:00:00 By Nasdaq GlobeNewswire

Apellis and Sobi Report Empaveli™ (pegcetacoplan) Demonstrated Sustained Normalization of Clinical Measures in a Broad PNH Patient Population

13 Dec 2021 11:45:00 By Nasdaq GlobeNewswire

Apellis Pharmaceuticals to Present at the 4th Annual Evercore ISI HealthCONx Conference

29 Nov 2021 07:00:01 By Nasdaq GlobeNewswire

Apellis Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise of Option to Purchase Additional Shares

18 Nov 2021 16:01:00 By Nasdaq GlobeNewswire

Apellis Pharmaceuticals Announces Pricing of Public Offering of Common Stock

16 Nov 2021 07:00:01 By Nasdaq GlobeNewswire

Apellis Pharmaceuticals Announces Proposed Public Offering of Common Stock

15 Nov 2021 16:01:00 By Nasdaq GlobeNewswire

Apellis Reiterates Plans to Submit a New Drug Application in the First Half of 2022 for Pegcetacoplan for Geographic Atrophy Following FDA Feedback

12 Nov 2021 07:00:01 By Nasdaq GlobeNewswire